Results 1 to 10 of about 5,389,844 (359)
The Lancet, 2021 The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic landscape and biology underpinning both primary and metastatic prostate cancer. Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies ...
R. Rebello +8 more
semanticscholar +11 more sources
Ca, 2021 This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer.
H. Sung +6 more
semanticscholar +1 more source
Ca, 2023 Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer ...
R. Siegel +3 more
semanticscholar +1 more source
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Molecules, 2022 Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to late detection of the disease.
M. Sekhoacha +5 more
semanticscholar +1 more source
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
The Journal of the National Comprehensive Cancer Network, 2021 The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease.
E. Schaeffer +31 more
semanticscholar +1 more source
Ca, 2022 Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes.
R. Siegel +3 more
semanticscholar +1 more source
Accuracy of elastic fusion biopsy in daily practice: results of a multicenter study of 2115 patients [PDF]
, 2018 OBJECTIVES: To assess the accuracy of Koelis fusion biopsy for the detection of prostate cancer and clinically significant prostate cancer in the everyday practice.
Albisinni S +30 more
core +1 more source
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
New England Journal of Medicine, 2004 BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival.
I. Tannock +11 more
semanticscholar +1 more source
Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]
, 2014 Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G +16 more
core +2 more sources
Increased survival with enzalutamide in prostate cancer after chemotherapy.
New England Journal of Medicine, 2012 BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher +19 more
semanticscholar +1 more source